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In nitric oxide synthase (NOS) incubates, superoxide (O32 )
may be produced in addition to nitric oxide (NO). NO and
O32 react together to form peroxynitrite (ONOO
3). The re-
action of NO and ONOO3 with GSH may lead to low-yield
formation of S-nitrosoglutathione (GSNO) and S-nitrogluta-
thione (GSNO2) [1], respectively. Consequently, it can be ex-
pected that in the presence of GSH, formation of GSNO and
GSNO2 would occur in NOS incubates. Indeed, on the basis
of HPLC and electrochemical detection, formation of GSNO
in NOS incubates has been reported [2,3]. However, it is not
unequivocally evident that GSNO had been formed in these
studies, because GSNO and GSNO2 possess almost identical
physicochemical properties including co-elution in various
HPLC systems [1]. Independent of this, quantitation by
HPLC revealed that GSNO formation amounted to 5% at
2 mM GSH and 47% at 7 mM GSH with respect to L-citrul-
line [2]. GSNO has been reported to being formed enzymati-
cally at 3 WM in NOS incubates in the presence of 1 mM
GSH, and quantitation by an NO electrode yielded a
GSNO production rate of 25^45% with respect to that of
L-citrulline [3]. Thus, the reported GSNO production is con-
siderably higher than the expected GSNO/GSNO2 formation
from GSH and NO or ONOO3. This discrepancy was ex-
plained by the assumption that not ONOO3 but a species like
NO/O32 produced by NOS was very e⁄cient in producing
GSNO from GSH [3].
Analysis of GSNO and other S-nitroso compounds in ni-
trite- and thiol-containing matrices, such as in NOS incubates,
is associated with many problems stemming from their facile
artifactual formation under acidic conditions [5], which usu-
ally prevail both during sample preparation [4] and HPLC
analysis [2,3,5]. The potential artifactual formation of
GSNO in GSH- and nitrite-rich matrices prompted us to in-
vestigate formation of GSNO in NOS incubates. We used
experimental conditions almost identical with those described
for NOS incubates [2,3] and quantitated by GC-MS
[15N]nitrite and GS15NO formation in incubates of a neuronal
NOS using L-[15N2]arginine.
NOS-dependent [15N]nitrite amounted to (mean þ S.D.,
n = 2) 0.59 þ 0.15 WM (at 5 Wg/ml NOS) and 1.29 þ 0.10 WM
(at 10 Wg/ml NOS). Analysis by HPLC system A (pH 7) and
GC-MS showed [15N]nitrite as the major and GS15NO as the
minor product (29 nM and 42 nM, respectively) resulting in
molar ratios of [15N]nitrite to GS15NO of 20:1 and 31:1,
respectively (Fig. 1A). This ¢nding disagrees with that previ-
ously reported [3]. Analysis of an NOS incubate by HPLC
system B (pH 2) and GC-MS revealed signi¢cant formation
of GS15NO besides [15N]nitrite in dependence on L-[15N2]-
arginine concentration (Fig. 1B). At 10 WM of L-[15N2]-
arginine, [15N]nitrite and GS15NO were measured at 3.7 WM
and 0.8 WM, respectively, resulting in a [15N]nitrite to GS15NO
molar ratio of 4.6:1. At 100 WM of L-[15N2]arginine,
[15N]nitrite and GS15NO were measured at 34.2 WM and
8.5 WM, respectively, resulting in a [15N]nitrite to GS15NO
molar ratio of 4.0:1. Injection of a bu¡ered solution of
GSH (3 mM) and [15N]nitrite (34 WM) into HPLC system A
(pH 7) did not result in detectable amounts of GS15NO, but
analysis by HPLC system B (pH 2) resulted in formation of
7.7 WM of GS15NO, i.e. 23% of [15N]nitrite was converted to
GS15NO. These ¢ndings strongly suggest that the greatest
part of GS15NO measured in the second experiment (i.e. B)
was formed artifactually. The possibility that the major part
of GS15NO formed in the ¢rst experiment (i.e. A) could had
been decomposed during incubation is refuted, because
GS15NO is relatively stable in NOS incubates (Fig. 1C).
Ammonium sulfamate is frequently used to eliminate nitrite
prior to detection of S-nitroso compounds under acidic con-
ditions [3,4], under which artifactual formation of GSNO
from GSH and unremoved nitrite has been observed [4]. We
con¢rm this ¢nding. Acidi¢cation of 50 mM phosphate bu¡-
ered solutions of GSH (1 mM), nitrite (100 WM) and ammo-
nium sulfamate (0.1, 1.0 or 10 mM ¢nal concentration) (pH 7)
with o-phosphorous acid to pH 3 followed by analysis with
HPLC system A revealed time-dependent formation of GSNO
(48, 27 and 5 WM, respectively, 20 min after acidi¢cation).
Our results demonstrate that GSNO/GSNO2 are formed in
NOS incubates in the presence of GSH, however, at concen-
trations considerably lower than those reported previously by
other groups [2,3]. Our results also show potential artifactual
formation of GSNO both during sample treatment and HPLC
analysis under acidic conditions. GSNO and GSNO2 exhibit
NO-like activities, but GSNO and GSNO2 are several orders
of magnitude more stable than NO. Thus, the concentration
of long-lived GSNO and GSNO2 in NOS incubates, and ex-
pectedly in NOS-producing cells, too, could be higher than
that of the short-lived NO. Therefore, the GSNO/GSNO2
pathway could be more signi¢cant than the NO pathway.
More detailed investigation of the (bio)chemical mechanisms
of the GSNO/GSNO2 generation from NOS and its quantita-
tive relationship to NO using artifactual-free analytical meth-
ods and detection techniques such as HPLC at neutral or
alkaline pH and mass spectrometry should increase our
understanding of the biological signi¢cance of the GSNO/
GSNO2 pathway. According to the present knowledge, a pre-
requisite for the formation of GSNO2 in NOS incubates is the
simultaneous formation of NO and O32 . The NOS-catalyzed
formation of O32 has been, however, questioned [6]. The sig-
ni¢cance of O32 formation is enormous and its origin requires
pressing clari¢cation. Performance of careful experiments in-
cluding positive and negative control experiments is self-evi-
dent. The most crucial point, however, is the use of unobjec-
tionable, highly speci¢c, sensitive and interference-free
analytical methods. In our opinion, these are the most chal-
lenging tasks in the ¢eld of NO research.
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Note from the Editorial O⁄ce: FEBS Letters has recently
published several articles of Correspondence regarding the
technical di⁄culties of measuring byproducts formed from
NOS incubates. In order to make space for Correspondence
on other topics, we are not interested in continuing the NOS
discussion further at this point in time.
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Platelet activation: a new vascular
activity of anandamide
Mauro Maccarrone, Alessandro Finazzi-Agro'*
Endocannabinoids are amides and esters of long chain
polyunsaturated fatty acids, which act as mediators in brain
and peripheral tissues through the binding to cannabinoid
receptors. Anandamide (N-arachidonylethanolamine, AEA)
is a major endocannabinoid, showing cardiovascular activity
[1] by induction of vasorelaxation [2]. Although AEA has
been described as an endothelium-derived hyperpolarizing fac-
tor (EDHF), this hypothesis was debated and recent data
suggest that EDHF is instead a cytochrome P450-metabolite
[3]. Whether or not an EDHF, AEA is likely to play an
important role in the control of vascular tone, as supported
also by the observation that both rat endothelial cells and
macrophages can release it [4].
We found and published in this journal [5] that AEA (91.2
mM) activates human platelets by a cannabinoid receptor-in-
dependent mechanism, which involves a rise in intracellular
calcium and does not depend on the arachidonate cascade. In
the same paper we showed that human platelets have the bio-
chemical machinery to degrade AEA, i.e. a high a⁄nity trans-
porter and a fatty acid amide hydrolase (FAAH). Afterwards,
these data have been largely con¢rmed by Braud et al. [6],
who found that AEA in rabbit platelets was active at physio-
logical concentrations (910 WM) when used in combination
with CaCl2 and ¢brinogen. These authors attributed the ag-
gregating e¡ect of AEA to its cleavage into arachidonic acid
Fig. 1. A: Peak area ratio of m/z 47 (for [15N]nitrite and GS15NO)
to m/z 46 (for nitrite and GSNO) determined in 0.25-min HPLC
fractions collected from the analysis of a 200-Wl aliquot of an NOS
incubate (pH 7; 37‡C) containing: NOS, 5 or 10 Wg/ml; L-
[15N2]arginine, 100 WM; NADPH, 50 WM; calmodulin, 600 nM;
CaCl2, 600 WM; and GSH, 1 mM. The incubation time was 10
min. HPLC system A with a mobile phase pH of 7.0 was used. Val-
ues are shown as mean þ S.D. from two experiments. In the right
panel, the y-axis of the chromatogram is ampli¢ed by a factor of
six as compared with that of the left panel. B: Peak area ratio of
m/z 47 to m/z 46 measured in 1-min HPLC fractions collected from
the analysis of a 200-Wl aliquot of an NOS incubate (pH 7; 37‡C)
containing: NOS, 13 Wg/ml; L-[15N2]arginine, 10 or 100 WM;
NADPH, 800 WM; calmodulin, 500 nM; CaCl2, 500 WM; FAD,
5 WM; FMN, 5 WM; H4B, 10 WM; and GSH, 1 mM. The incuba-
tion time was 30 min. The control sample contained all compounds
except for NOS. HPLC system B with a mobile phase pH of 2.0
was used. C: Stability of synthetic GS15NO in an NOS incubate
(pH 7; 37‡C) that contained all compounds as described in B. The
£ow rate was 1 ml/min in both HPLC systems.
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by an AEA-degrading enzyme [6]. At any extent, these data
suggest that AEA is an unlikely physiological agonist of plate-
lets, but it can rather act in vivo as a co-agonist in combina-
tion with other ‘classical’ aggregating molecules such as ara-
chidonic acid, ¢brinogen or thrombin [5,6]. However, the role
of endocannabinoids in the cross-talk between platelets and
endothelium, which might be crucial in thrombosis, still
awaits clari¢cation.
Platelet activation by AEA appears of interest also because
it can be released from endothelial cells and macrophages in
rats [4]. This suggests an interplay between di¡erent blood
cells in regulating the peripheral endocannabinoid system,
hence the cardiovascular activities of these newly discovered
lipid mediators [1^4]. In keeping with this concept, we showed
that peripheral human cells such as lymphoma (U937) cells
[7], lymphocytes [8], endothelial (HUVEC) cells [9] and mas-
tocytes (HMC-1) [10] take up AEA and degrade it through
FAAH. The apparent kinetic constants of FAAH in human
blood cells (Table 1) suggest that a similar enzyme is ex-
pressed to di¡erent extents, showing similar Km but di¡erent
Vmax values (Table 1). Finally, it should be stressed that plate-
let activation is paralleled by a decrease in nitric oxide, which
stimulates AEA uptake by human cells [7^10]. Therefore,
platelets can a¡ect endocannabinoid degradation by the
neighboring blood cells, contributing to the control of these
compounds.
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Table 1
Kinetic parameters of FAAH activity in human peripheral cells
Human cells Km (WM) Vmax (pmol min31 mg protein31) Reference
Platelets 10 þ 1.0 270 þ 30 [5]
Lymphoma cells (U937) 6.5 þ 0.6 520 þ 50 [7]
Lymphocytes 8.0 þ 1.0 187 þ 20 [8]
Endothelial cells (HUVEC) 7.0 þ 0.7 25 þ 3 [9]
Mast cells (HMC-1) 5.0 þ 0.5 160 þ 15 [10]
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